Abstract
Emerging evidence suggests that epoetin alfa can be administered at extended intervals of up to 4 wk. This open-label, randomized study was performed to characterize the pharmacokinetic and pharmacodynamic profiles of four dosing regimens of epoetin alfa administered subcutaneously in anemic patients who had chronic kidney disease and were not on dialysis. Thirty-eight patients, enrolled from nine centers in the United States, were > or =18 yr of age and had hemoglobin <11.0 g/dl and GFR 12 to 60 ml/min per 1.73 m(2). Patients received one of four epoetin alfa dosing regimens: 50 IU/kg three times per week, 10,000 IU once weekly, or 20,000 IU every 2 wk for 36 d or 40,000 IU every 4 wk for 64 d. Each regimen provided a similar dosage of epoetin alfa over 4 wk. Dosage adjustments were not permitted. Drug exposure to epoetin alfa over 4 wk, based on area under the curve, was somewhat higher with the extended interval regimens compared with the three-times-weekly regimen. Mean change in hemoglobin during the study period was similar for all regimens. No patients were transfused. Three patients experienced five serious adverse events, none of which was considered treatment related. Extended dosing interval regimens of epoetin alfa ...Continue Reading
References
Dec 1, 1989·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·V S LimR L DeGowin
Feb 1, 1995·Drugs·A Markham, H M Bryson
Nov 3, 1998·Clinical Pharmacology and Therapeutics·W K CheungM C Wacholtz
Jun 22, 2002·Archives of Internal Medicine·Brad C AstorJosef Coresh
Jul 1, 2004·Clinical Nephrology·R ProvenzanoUNKNOWN POWER Study Group
Jun 30, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Michael GermainMario Curzi
Aug 24, 2005·Clinical Nephrology·R ProvenzanoUNKNOWN PROMPT Study Group
Jan 27, 2007·Clinical Pharmacokinetics·Per Olsson-GisleskogJuan Jose Perez-Ruixo
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Robert BenzMarsha Wolfson
Apr 11, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Bruce SpinowitzUNKNOWN Epoetin Alfa Extended Dosing Study Group
Citations
Feb 22, 2011·BMC Nephrology·Luca GabuttiMichel Burnier
Nov 12, 2010·Clinical Drug Investigation·Jaya GobinDavid B Simon
Oct 8, 2009·Clinical Journal of the American Society of Nephrology : CJASN·Pablo E PergolaPeter Bowers
Feb 27, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Pablo E PergolaPeter Bowers
Sep 30, 2009·World Journal of Gastroenterology : WJG·Rosario Moreno LópezFernando Gomollón García
Jul 28, 2009·Lancet·Hiroshi NonoguchiTakeshi Nakanishi
Oct 24, 2015·Journal of the American Society of Nephrology : JASN·Louis HoldstockAlexander R Cobitz
Jul 7, 2015·BioMed Research International·Natasha IrreraDomenica Altavilla
Oct 10, 2008·Orvosi hetilap·Zoltán KissIstván Kiss
Jun 9, 2015·Molecular Therapy : the Journal of the American Society of Gene Therapy·Andreas ThessThomas Schlake
Apr 17, 2018·PLoS Computational Biology·Joydeep SarkarGerald M Saidel
Jan 10, 2017·The Cochrane Database of Systematic Reviews·Deirdre HahnElisabeth M Hodson
Jun 27, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Rowan G Walker
Jan 9, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Richard J GlassockSilvio H Barberato
Mar 12, 2010·Journal of Clinical Pharmacology·Kenneth MaieseJinling Hou
Mar 13, 2018·Journal of Korean Neurosurgical Society·Won-Sang ChoUNKNOWN Korean Stroke Society and Korean Academy of Rehabilitation Medicine
Apr 17, 2017·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Meredith A Atkinson, Bradley A Warady
Oct 18, 2019·BMC Nephrology·Christine K BaileyVickas V Patel
May 19, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Vinothkumar GVenkataraman P
May 7, 2021·Drug Design, Development and Therapy·Inseung JeonSeungHwan Lee